BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19058032)

  • 1. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
    Delellis RA
    Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center.
    Juhlin CC; Nilsson IL; Lagerstedt-Robinson K; Stenman A; Bränström R; Tham E; Höög A
    Mod Pathol; 2019 Jul; 32(8):1082-1094. PubMed ID: 30923346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
    Cetani F; Marcocci C; Torregrossa L; Pardi E
    Endocr Relat Cancer; 2019 Jul; 26(7):R441-R464. PubMed ID: 31085770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
    Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
    Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
    Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
    Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
    Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
    Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of de novo germline mutations in the HRPT2 gene in two apparently sporadic cases with challenging parathyroid tumor diagnoses.
    Cavaco BM; Santos R; Félix A; Carvalho D; Lopes JM; Domingues R; Sirgado M; Rei N; Fonseca F; Santos JR; Sobrinho L; Leite V
    Endocr Pathol; 2011 Mar; 22(1):44-52. PubMed ID: 21360064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
    Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
    Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
    Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
    World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining a molecular phenotype for benign and malignant parathyroid tumors.
    Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
    Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
    Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
    PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
    Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
    J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid carcinoma: an overview.
    DeLellis RA
    Adv Anat Pathol; 2005 Mar; 12(2):53-61. PubMed ID: 15731573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.